Cellceutix CEO Discusses Autism Drug, Kevetrin and Progressions with CEOCFO Interviews and News

BEVERLY, MA–(Marketwire – June 3, 2010) – Cellceutix Corporation (OTCBB: CTIX) is pleased to announce that its Chief Financial Officer, Leo Ehrlich, has been featured in an interview with leading online financial publication, CEOCFO Interviews and News. The interview was conducted by CEOCFO Senior Editor Lynn Fosse and highlighted the uniqueness of Cellceutix and the details that make it stand out from all other biotechnology companies in the industry.

In the interview, Mr. Ehrlich discusses the progressions of KM-391, Cellceutix’s compound for the treatment of autism, and Kevetrin, their drug being developed as a treatment for drug-resistant cancers. Mr. Ehrlich explained why their autism drug is revolutionary as there is no drug available today for the treatment of autism. Additionally, Mr. Ehrlich also discusses the company’s growth strategy as it relates to future potential partnerships, shareholder value and the strength of the Cellceutix management team.

“We are not dealing with just another cancer drug; we have indications that it is effective against drug-resistant cancers, which is a multibillion dollar market,” Mr. Ehrlich explained. ”Most cancer drugs currently out there are just another variation of existing cancer drugs, whether they be another platinum based drug or another Taxol. We, however, have a completely new and novel compound.”

“We are pleased to have been interviewed by CEOCFO. The interview provides us another opportunity to showcase to our shareholders the many milestones we are achieving and the progressions of our business strategy,” commented Mr. Ehrlich.